跳至主要内容
临床试验/NCT00836160
NCT00836160已完成不适用

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

AstraZeneca1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2009年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
36
试验地点
1
主要终点
PFS of the third-line therapy

研究概览

简要总结

This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addition, the assignment of the patient to a particular therapy or therapeutic strategy is not decided in advance by this study protocol, but falls within current practice.

The patient who fulfils eligible criteria will be enrolled when starts to receive the second-line EGFR-TKI therapy. The frequency of tumor response evaluation by RECIST criteria follows the investigator's discretion as daily practice.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least one measurable lesion according to RECIST criteria
  • Histologically or cytologically confirmed NSCLC of adeno histology
  • Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce

排除标准

  • 未提供

结局指标

主要结局

PFS of the third-line therapy

时间窗: 9 months

次要结局

  • Overall objective tumor response (complete response [CR] + partial response [PR]) of the third-line therapy by RECIST criteria(9 months)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验